Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-	-	3.11	12.29	4.31	-
Revenue Growth (YoY)	-	-	-74.67%	185.26%	-	-
Cost of Revenue	16.89	17.11	17.88	18.99	17.85	24.76
Gross Profit	-16.89	-17.11	-14.77	-6.7	-13.54	-24.76
Selling, General & Admin	10.52	11.77	13.87	14.7	13.95	16.2
Operating Expenses	7.72	11.77	13.87	14.7	13.95	16.2
Operating Income	-24.6	-28.88	-28.64	-21.4	-27.49	-40.96
Other Non Operating Income (Expenses)	0.59	0.58	-1.53	-8.01	-1.33	-2.1
EBT Excluding Unusual Items	-24.01	-28.3	-30.17	-29.41	-28.82	-43.06
Gain (Loss) on Sale of Assets	-	9.65	-	-	-	-
Other Unusual Items	-	-	37.18	-	-2.1	-
Pretax Income	-24.01	-18.65	7.01	-29.41	-30.92	-43.06
Earnings From Continuing Operations	-24.01	-18.65	7.01	-29.41	-30.92	-43.06
Earnings From Discontinued Operations	0.29	1.24	1.01	0.95	13.17	2.62
Net Income	-23.72	-17.41	8.03	-28.46	-17.75	-40.45
Net Income to Common	-23.72	-17.41	8.03	-28.46	-17.75	-40.45
Free Cash Flow	-23.28	-11.73	-21.05	-22.39	-29.41	-42.54
Gross Margin	-	-	-	-54.52%	-	-
Operating Margin	-	-	-919.75%	-174.10%	-638.06%	-
Profit Margin	-	-	257.77%	-231.51%	-411.93%	-
Free Cash Flow Margin	-	-	-676.01%	-182.17%	-682.43%	-
EBITDA	-24.21	-28.31	-27.74	-20.26	-26.19	-39.53
EBITDA Margin	-	-	-	-164.79%	-	-
D&A For EBITDA	0.4	0.57	0.9	1.14	1.31	1.44
EBIT	-24.6	-28.88	-28.64	-21.4	-27.49	-40.96
EBIT Margin	-	-	-	-174.10%	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.